<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00915850</url>
  </required_header>
  <id_info>
    <org_study_id>WMU-EC01</org_study_id>
    <nct_id>NCT00915850</nct_id>
  </id_info>
  <brief_title>Trial of Docetaxel, Cisplatin, Fluorouracil (5-FU) for Unresectable Advanced Esophageal Squamous Cell Carcinoma (ESCC)</brief_title>
  <official_title>Phase I/II Trial of Combination Chemotherapy With Docetaxel, Cisplatin and 5-FU for Unresectable Advanced Esophageal Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wakayama Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wakayama Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II study is being conducted to determine the maximum-tolerated dose (MTD),&#xD;
      dose-limiting toxicity (DLT), and efficacy of a combination chemotherapy using docetaxel,&#xD;
      cisplatin and 5-fluorouracil (DCF) in unresectable advanced esophageal cancer. The usefulness&#xD;
      of the this regimen is evaluated by RECIST, time to progression and median survival time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      &lt;Phase I&gt;&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      To establish the safety of combination chemotherapy comprising docetaxel (escalating doses:&#xD;
      25,30,35,40 mg/m2,day1 and day8), cisplatin (12mg/m2,day1-5), and fluorouracil&#xD;
      (600mg/m2,day1-5) (DCF) in unresectable advanced esophageal cancer.&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      To observe the efficacy of this regimen in these patients.&#xD;
&#xD;
      &lt;Phase II&gt;&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      To assess the response rate of combination chemotherapy comprising docetaxel (recommended&#xD;
      dose determined in phase I study,day1 and day8), cisplatin (12 mg/m2, day1-5), and&#xD;
      fluorouracil (600 mg/m2, day1-5) (DCF) in unresectable advanced esophageal cancer.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To determine the adverse reactions of this regimen in these patients. To determine TTP(Time&#xD;
      to progression) of patients treated with this regimen. To determine MST(Median survival time)&#xD;
      of patients treated with this regimen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2007</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (Phase I: toxicities as assessed by NCI CTCAE version3) and efficacy (Phase II: Feasibility as evaluated by RECIST)</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the recommended phase II dose of docetaxel (Phase I)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the clinical effectiveness in the patients with measurable disease (Phase I)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To analyze the toxicity (Phase II)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (Phase II)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>median survival time (Phase II)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Anticancer drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>docetaxel, cisplatin and 5-FU</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCF</intervention_name>
    <description>docetaxel, Cisplatin and 5-FU</description>
    <arm_group_label>Anticancer drug</arm_group_label>
    <other_name>docetaxel+Cisplatin+5-FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  locally advanced or metastatic esophageal cancer precluding curative surgical&#xD;
             resection and recurrent esophageal cancer measurable disease by CT scan&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  20 years and older&#xD;
&#xD;
          -  Patients must have clinically documented unresectable or metastatic esophageal cancer&#xD;
             and histologic confirmation of the diagnosis with tumor&#xD;
&#xD;
          -  Tissue from tumor must be available&#xD;
&#xD;
          -  Patients must have measurable disease&#xD;
&#xD;
          -  Patients may have received prior adjuvant chemotherapy; this must have been completed&#xD;
             at least 1 month&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Laboratory values as follows&#xD;
&#xD;
          -  3000/mm3 &lt; WBC &lt; 12000/mm3&#xD;
&#xD;
          -  1500/mm3 &lt; granulocyte count&#xD;
&#xD;
          -  8.0 gm/dl &lt; hemoglobin&#xD;
&#xD;
          -  Platelet count &gt; 100000/mm3&#xD;
&#xD;
          -  Aspartate transaminase &lt; 150 IU/L&#xD;
&#xD;
          -  Alanine transaminase &lt; 150 IU/L&#xD;
&#xD;
          -  Creatinine &lt; 1.5 mg/dl&#xD;
&#xD;
          -  Able and willing to give valid written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy (women of childbearing potential: refusal or inability to use effective&#xD;
             means of contraception)&#xD;
&#xD;
          -  Active or uncontrolled infection&#xD;
&#xD;
          -  Prior chemotherapy or radiation therapy within 4 weeks, surgery within 3 weeks or&#xD;
             immunotherapy within 1 week&#xD;
&#xD;
          -  Clinically significant heart disease&#xD;
&#xD;
          -  Patients with a history of myocardial infarction within the previous three months&#xD;
&#xD;
          -  Patients with uncontrolled diabetes mellitus or hypertension&#xD;
&#xD;
          -  Presence of clinically apparent central nervous system metastases&#xD;
&#xD;
          -  Patients with any other severe concurrent disease, which in the judgment of the&#xD;
             investigator, would make the patient inappropriate for entry into this study&#xD;
&#xD;
          -  Decision of unsuitableness by principal investigator or physician-in-charge&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Makoto Iwahashi, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Second Department of Surgery, Wakayama Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Makoto Iwahashi, MD</last_name>
    <phone>81-73-441-0613</phone>
    <email>makoto@wakayama-med.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wakayama Medical University</name>
      <address>
        <city>Wakayama</city>
        <zip>641-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Makoto Iwahashi, MD</last_name>
      <phone>81-73-441-0613</phone>
      <email>makato@wakayama-med.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>June 5, 2009</study_first_submitted>
  <study_first_submitted_qc>June 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2009</study_first_posted>
  <last_update_submitted>September 8, 2010</last_update_submitted>
  <last_update_submitted_qc>September 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Makoto Iwahasi</name_title>
    <organization>Wakayama Medical University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

